Ganymed, aTyr gain new venture funds

Germany's Ganymed Pharmaceuticals has raised $45.5 million in its third round of venture capital. Much of that money will back the company's experimental cancer therapies. The cash will fund Ganymed's lead candidate GC182 through Phase I/IIa clinical testing in gastric cancer. And Ganymed researchers will push the GT468 project into Phase I/IIa in a major cancer indication. The round was led by VI Partners, a Swiss-based venture capital firm.

- check out the release

ALSO: San Diego-based aTyr Pharma has raised $10.5 million in its second round of venture capital. The round was co-led by Alta Partners in San Francisco and Polaris Venture Partners in Boston. aTyr was founded by Paul Schimmel Ph.D., Professor at The Scripps Research Institute, John Clarke of Cardinal Partners, and colleagues. The company is targeting a family of cellular proteins that have demonstrated therapeutic potential. "aTyr presents a rich opportunity to identify and develop new protein biologics with the potential to address numerous pathogenic processes," said Dr. Schimmel. Release

Related Articles:
Biotech sees red-hot growth in U.S., Europe. Report
Biotech venture funding jumped in '06. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.